Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse - European Medical Journal

Continue

Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse

Oncology
At the European Cancer Congress (ECC) 2015, Paul Nathan, MB.BS, BSc (Hons), BA, PhD, FRCP, of Mount Vernon Cancer Centre, Northwood, UK, discusses a study that was designed to determine whether seropositivity to a panel of tumour antigens was associated with a risk of relapse in patients with stage II and III melanoma.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given